PDCD1 and hepatocellular carcinoma: Recently, two types of anti‐PD‐1 monoclonal antibodies, nivolumab and pembrolizumab, have been FDA-approved as second‐line therapies for advanced HCC, and a small percentage of patients have achieved complete remission (CR), resulting in long-term survival 53, 54.